Previous 10 | Next 10 |
Results show overall confirmed objective response rate (cORR) of 33%, disease control rate (DCR) of 92%, and median progression-free survival (mPFS) of 9.6 months Data support further investigation of zanidatamab in combination with palbociclib and fulvestrant as a potential chemotherapy-...
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, announced today that it has elected to transfer its stock exchange listing from the New York Stock Exchange (NYSE) to The Nasdaq Stock Market LLC (Nasdaq), where the vast majority o...
FN Media Group Presents USA News Group News Commentary Vancouver, BC –November 30, 2022 – USA News Group – A new study has revealed that women diagnosed with benign breast disease through screening have an almost double risk of acquiring breast cance...
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that the waiting period under the Hart-Scott-Rodino (HSR) Antitrust Improvements Act of 1976, as amended, for the previously announced license agreement ...
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced the publication of an abstract highlighting new clinical data for zanidatamab, a HER2-targeted bispecific antibody. Zanidatamab in combination with palboci...
Summary Two new Breakout Stocks for Week 46 with better than 10% short-term upside potential and a Dow 30 Pick. Average cumulative returns now up to +116.9% YTD. This week two picks gained 10% in less than a week with MAG +14.9% and CLNE +15.4% for total portfolio gains over 5%. ...
Zymeworks Inc. (ZYME) Q3 2022 Results Conference Call November 08, 2022 04:30 PM ET Company Participants Jack Spinks - Head of Investor Relations Neil Klompas - President & COO Kenneth Galbraith - Chair and CEO Neil Josephson - CMO Paul Moore - Chief ...
The following slide deck was published by Zymeworks Inc. in conjunction with their 2022 Q3 earnings call. For further details see: Zymeworks Inc. 2022 Q3 - Results - Earnings Call Presentation
Zymeworks press release ( NYSE: ZYME ): Q3 Non-GAAP EPS of -$0.66 beats by $0.31 . Revenue of $2.6M (-40.9% Y/Y) misses by $1.95M . For further details see: Zymeworks Non-GAAP EPS of -$0.66 beats by $0.31, revenue of $2.6M misses by $1.95M
Announced exclusive license agreement with Jazz Pharmaceuticals to develop and commercialize zanidatamab, Zymeworks’ lead clinical candidate, for total potential payments of up to $1.76 billion, plus royalties on net sales Hosted Early Research and Development day highlight...
News, Short Squeeze, Breakout and More Instantly...
VANCOUVER, British Columbia, July 22, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that the Un...
VANCOUVER, British Columbia, July 11, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that manage...
VANCOUVER, British Columbia, June 17, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that the Un...